Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) Short Interest Update

Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) saw a large increase in short interest during the month of May. As of May 29th, there was short interest totaling 310 shares, an increase of 3,344.4% from the May 14th total of 9 shares. Based on an average trading volume of 2,834 shares, the short-interest ratio is currently 0.1 days. Approximately 0.0% of the company’s stock are sold short.

Enzon Pharmaceuticals Price Performance

OTCMKTS ENZN remained flat at $5.75 during mid-day trading on Tuesday. 1,857 shares of the company were exchanged, compared to its average volume of 1,920. Enzon Pharmaceuticals has a 52 week low of $1.50 and a 52 week high of $12.99. The business’s 50-day moving average price is $6.03 and its two-hundred day moving average price is $5.58. The company has a quick ratio of 1.16, a current ratio of 2.01 and a debt-to-equity ratio of 0.42.

Enzon Pharmaceuticals (OTCMKTS:ENZN) last posted its earnings results on Monday, May 4th. The biotechnology company reported ($0.84) EPS for the quarter. The business had revenue of $86.54 million for the quarter.

About Enzon Pharmaceuticals

Enzon Pharmaceuticals, Inc, headquartered in Piscataway, New Jersey, is a specialized biopharmaceutical company best known for pioneering polyethylene glycol (PEG) technology to enhance the pharmacokinetic properties of therapeutic proteins. Founded in 1981, Enzon has leveraged its PEGylation platform to develop an array of oncology and hematology products with improved half-life and reduced immunogenicity.

The company’s flagship product, Oncaspar (pegaspargase), was originally approved for the treatment of acute lymphoblastic leukemia in pediatric and adult patients, highlighting Enzon’s commitment to oncology.